questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
Alcohol oxidoreductases
NAD (+) and NADP (+) dependent Alcohol oxidoreductases
3-Hydroxyacyl-CoA dehydrogenases
Hydroxymethylglutaryl-CoA reductases
Hydroxymethylglutaryl-CoA reductases, NADP-dependent
Hydroxymethylglutaryl-CoA reductases, NADP-dependent : Questions médicales fréquentes
Diagnostic
5
Déficience enzymatique
Tests génétiques
Cholestérol
Tests sanguins
Fatigue
Anomalies lipidiques
Marqueurs biologiques
Dyslipidémie
Antécédents familiaux
Maladies métaboliques
Symptômes
5
Fatigue
Troubles du métabolisme lipidique
Douleurs musculaires
Dysfonction enzymatique
Éruptions cutanées
Troubles lipidiques
Prévention
5
Prévention
Alimentation saine
Bilans de santé
Anomalies lipidiques
Éducation à la santé
Santé lipidique
Antécédents familiaux
Surveillance
Traitements
5
Médicaments hypolipémiants
Régime alimentaire
Thérapie génique
Déficience enzymatique
Alimentation
Gestion des lipides
Effets secondaires
Douleurs abdominales
Complications
5
Hyperlipidémie
Maladies cardiovasculaires
Maladies cardiaques
Risque
Diabète
Troubles lipidiques
Troubles hépatiques
Accumulation de lipides
Gestion des complications
Traitements médicaux
Facteurs de risque
5
Mode de vie sédentaire
Risque
Antécédents familiaux
Maladies métaboliques
Stress
Métabolisme lipidique
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent : Questions médicales les plus fréquentes",
"headline": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hydroxymethylglutaryl-CoA reductases, NADP-dependent : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-09",
"dateModified": "2026-03-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases",
"url": "https://questionsmedicales.fr/mesh/D006903",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases",
"code": {
"@type": "MedicalCode",
"code": "D006903",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025782",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yoko Kimata-Ariga",
"url": "https://questionsmedicales.fr/author/Yoko%20Kimata-Ariga",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry, College of Agriculture, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yoshida, Yamaguchi, Japan."
}
},
{
"@type": "Person",
"name": "Russell A DeBose-Boyd",
"url": "https://questionsmedicales.fr/author/Russell%20A%20DeBose-Boyd",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "Masayuki Miyata",
"url": "https://questionsmedicales.fr/author/Masayuki%20Miyata",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry, College of Agriculture, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yoshida, Yamaguchi, Japan."
}
},
{
"@type": "Person",
"name": "George Davey Smith",
"url": "https://questionsmedicales.fr/author/George%20Davey%20Smith",
"affiliation": {
"@type": "Organization",
"name": "Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom."
}
},
{
"@type": "Person",
"name": "Rina Shinkoda",
"url": "https://questionsmedicales.fr/author/Rina%20Shinkoda",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry, College of Agriculture, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yoshida, Yamaguchi 753-8515, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Hydroxymethylglutaryl-CoA reductase activity is essential for mitochondrial β-oxidation of fatty acids to prevent lethal accumulation of long-chain acylcarnitines in the mouse liver.",
"datePublished": "2024-04-19",
"url": "https://questionsmedicales.fr/article/38641905",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bph.16363"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictive Modeling of HMG-CoA Reductase Inhibitory Activity and Design of New HMG-CoA Reductase Inhibitors.",
"datePublished": "2023-07-18",
"url": "https://questionsmedicales.fr/article/37546661",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acsomega.3c02567"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mitochondrial 3-hydroxymethylglutaryl-CoA synthase-2 (HMGCS2) deficiency: a rare case with bicytopenia and coagulopathy.",
"datePublished": "2023-11-06",
"url": "https://questionsmedicales.fr/article/37931961",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2023-257011"
}
},
{
"@type": "ScholarlyArticle",
"name": "HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.",
"datePublished": "2023-07-27",
"url": "https://questionsmedicales.fr/article/37541087",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bbrc.2023.07.056"
}
},
{
"@type": "ScholarlyArticle",
"name": "HMG-CoA reductase inhibitor from the endophytic fungus",
"datePublished": "2023-12-18",
"url": "https://questionsmedicales.fr/article/38105709",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14786419.2023.2289085"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D000429"
},
{
"@type": "ListItem",
"position": 6,
"name": "NAD (+) and NADP (+) dependent Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D064430"
},
{
"@type": "ListItem",
"position": 7,
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"item": "https://questionsmedicales.fr/mesh/D015094"
},
{
"@type": "ListItem",
"position": 8,
"name": "Hydroxymethylglutaryl-CoA reductases",
"item": "https://questionsmedicales.fr/mesh/D006903"
},
{
"@type": "ListItem",
"position": 9,
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"item": "https://questionsmedicales.fr/mesh/D025782"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hydroxymethylglutaryl-CoA reductases, NADP-dependent - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"description": "Comment diagnostiquer une déficience en HMG-CoA réductase ?\nQuels tests sanguins sont utilisés pour évaluer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nY a-t-il des marqueurs biologiques spécifiques ?\nComment les antécédents familiaux influencent-ils le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D025782#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"description": "Quels sont les symptômes d'une dysfonction de l'enzyme ?\nLes douleurs musculaires sont-elles fréquentes ?\nPeut-on observer des anomalies dans les tests de cholestérol ?\nY a-t-il des signes cutanés associés ?\nLes symptômes varient-ils selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D025782#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"description": "Comment prévenir les troubles liés à l'enzyme ?\nLes bilans de santé réguliers sont-ils importants ?\nL'éducation sur la santé lipidique est-elle cruciale ?\nLes antécédents familiaux nécessitent-ils une attention particulière ?\nLes habitudes de vie influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D025782#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"description": "Quels traitements sont disponibles pour les troubles liés à l'enzyme ?\nLes statines sont-elles efficaces dans ce cas ?\nDes thérapies géniques sont-elles envisagées ?\nComment l'alimentation influence-t-elle le traitement ?\nY a-t-il des effets secondaires aux traitements ?",
"url": "https://questionsmedicales.fr/mesh/D025782#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"description": "Quelles complications peuvent survenir en cas de dysfonction ?\nLes maladies cardiaques sont-elles une préoccupation ?\nY a-t-il un lien avec le diabète ?\nLes troubles hépatiques sont-ils possibles ?\nComment les complications sont-elles gérées ?",
"url": "https://questionsmedicales.fr/mesh/D025782#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLe mode de vie sédentaire est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe stress a-t-il un impact sur le risque ?",
"url": "https://questionsmedicales.fr/mesh/D025782#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en HMG-CoA réductase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic peut être établi par des tests génétiques et des analyses biochimiques."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour évaluer l'activité de l'enzyme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages des niveaux de cholestérol et de lipides dans le sang sont effectués."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des douleurs musculaires ou des anomalies lipidiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de certains lipides peuvent indiquer une dysfonction de l'enzyme."
}
},
{
"@type": "Question",
"name": "Comment les antécédents familiaux influencent-ils le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un historique familial de maladies métaboliques peut augmenter le risque et orienter le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une dysfonction de l'enzyme ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, douleurs musculaires, et troubles du métabolisme lipidique."
}
},
{
"@type": "Question",
"name": "Les douleurs musculaires sont-elles fréquentes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les douleurs musculaires peuvent être un symptôme courant de dysfonction enzymatique."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies dans les tests de cholestérol ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux de cholestérol peuvent indiquer une dysfonction de l'enzyme."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent parfois être observées en cas de troubles lipidiques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'âge et de la gravité de la condition."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés à l'enzyme ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine, l'exercice régulier et des bilans de santé peuvent aider à prévenir ces troubles."
}
},
{
"@type": "Question",
"name": "Les bilans de santé réguliers sont-ils importants ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans réguliers permettent de détecter précocement des anomalies lipidiques."
}
},
{
"@type": "Question",
"name": "L'éducation sur la santé lipidique est-elle cruciale ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur la santé lipidique aide à comprendre les risques et à adopter de bonnes habitudes."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux nécessitent-ils une attention particulière ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un historique familial de troubles lipidiques nécessite une surveillance accrue."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines peuvent réduire le risque de troubles liés à l'enzyme."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés à l'enzyme ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments hypolipémiants et des modifications du régime alimentaire."
}
},
{
"@type": "Question",
"name": "Les statines sont-elles efficaces dans ce cas ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les statines peuvent aider à réduire les niveaux de cholestérol et à améliorer la santé lipidique."
}
},
{
"@type": "Question",
"name": "Des thérapies géniques sont-elles envisagées ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sur les thérapies géniques sont en cours pour traiter les déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut aider à gérer les niveaux de lipides et à soutenir le traitement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements peuvent avoir des effets secondaires comme des douleurs abdominales ou des nausées."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir en cas de dysfonction ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme l'hyperlipidémie, les maladies cardiovasculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les maladies cardiaques sont-elles une préoccupation ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une dysfonction de l'enzyme peut augmenter le risque de maladies cardiaques."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec le diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles lipidiques peuvent contribuer au développement du diabète de type 2."
}
},
{
"@type": "Question",
"name": "Les troubles hépatiques sont-ils possibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles hépatiques peuvent survenir en raison d'une accumulation de lipides."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont gérées par des traitements médicaux et des modifications du mode de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le tabagisme, et une alimentation riche en graisses saturées."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de troubles lipidiques augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Le mode de vie sédentaire est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire augmente le risque de dysfonction de l'enzyme."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies métaboliques augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut influencer négativement le métabolisme lipidique."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 30/03/2026
Contenu vérifié selon les dernières recommandations médicales
6 publications dans cette catégorie
Affiliations :
Department of Biological Chemistry, College of Agriculture, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yoshida, Yamaguchi, Japan.
5 publications dans cette catégorie
Affiliations :
Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
3 publications dans cette catégorie
Affiliations :
Department of Biological Chemistry, College of Agriculture, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yoshida, Yamaguchi, Japan.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
3 publications dans cette catégorie
Affiliations :
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Chemistry, College of Agriculture, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yoshida, Yamaguchi 753-8515, Japan.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Division of Protein chemistry, Institute for Protein Research, Osaka University, Suita, Japan.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Division of Protein chemistry, Institute for Protein Research, Osaka University, Suita, Japan.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: mtkalc1@lsu.edu.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: gwaldro@lsu.edu.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Marine Biotechnology Research Centre, Korea Institute of Ocean Science and Technology, Busan, South Korea.
Department of Marine Biotechnology, KIOST School, University of Science and Technology, Daejeon, South Korea.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Marine Biotechnology Research Centre, Korea Institute of Ocean Science and Technology, Busan, South Korea.
Department of Marine Biotechnology, KIOST School, University of Science and Technology, Daejeon, South Korea.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Marine Biotechnology Research Centre, Korea Institute of Ocean Science and Technology, Busan, South Korea.
Department of Marine Biotechnology, KIOST School, University of Science and Technology, Daejeon, South Korea.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
National Institute for Health and Welfare, Helsinki, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom.
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
National Institute for Health Research, Oxford Biomedical Research Centre, Oxford University Hospital, Oxford, United Kingdom.
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Homerton College, University of Cambridge, Cambridge, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NADP-dependent" :
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR), and exert adverse effects on mitochondrial function, although the mechanisms underlying these e...
We established a new mouse strain using the Cre/loxP system, which enabled whole-body deletion of Hmgcr expression. These mice were crossed with Rosa26...
Lack of Hmgcr expression resulted in lethality, due to acute liver damage caused by rapid disruption of mitochondrial fatty acid β-oxidation and very high accumulation of long-chain (LC) acylcarnitine...
Our findings suggest that HMGCR is crucial for maintaining energy metabolism balance, and its activity is necessary for functional mitochondrial β-oxidation. Moreover, statin-induced adverse reactions...
As blood cholesterol increases, it accumulates in the intima of blood vessels, elevating the risk of atherosclerosis and coronary artery disease. Drugs that inhibit enzymes essential for cholesterol s...
Mitochondrial 3-hydroxymethylglutaryl-CoA synthase-2 (HMGCS2) is the main enzyme involved in ketogenesis. It is an essential enzyme for the catalysis of β-oxidation-derived-acetyl-CoA and acetoacetyl ...
Statins are cholesterol-lowering drugs that have exhibited potential as cancer therapeutic agents. However, as some cancer cells are resistant to statins, broadening an anticancer spectrum of statins ...
Two new fungal polyketides with unusual skeleton, collecapsins A and B (...
Poly-3-hydroxybutyrate (P(3HB)), a member of the polyhydroxyalkanoate (PHA) family, is a biodegradable polyester with diverse industrial applications. NADPH-dependent acetoacetyl-CoA reductase (phaB) ...
Traumatic brain injuries (TBIs) are associated with high morbidity and mortality due to both the original insult as well as the destructive biological response that follows. Medical management aims to...
Malonyl-CoA reductase utilizes two equivalents of NADPH to catalyze the reduction of malonyl-CoA to 3-hydroxypropionic acid (3HP). This reaction is part of the carbon fixation pathway in the phototrop...
Climate change is driving a search for environmentally safe methods to produce chemicals used in ordinary life. One such molecule is 3-hydroxypropionic acid, which is a platform industrial chemical us...
In the chloroplast stroma, dynamic pH changes occur from acidic to alkaline in response to fluctuating light conditions. We investigated the pH dependency of the electron transfer reaction of ferredox...